Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on February 22, 2024. The filing discloses modifications to the compensatory arrangements of the Company's executive officers, effective January 1, 2024, following an annual compensation review by the Compensation Committee and Board of Directors.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change reported is the increase in annual base salaries and the granting of equity awards to six executive officers. The specific adjustments are as follows:
- Jack A. Khattar (CEO): Base salary increased from $963,000 to $1,001,500. Received a 2023 bonus of $830,588, plus options for 322,000 shares and 193,200 PSUs.
- Timothy C. Dec (CFO): Base salary increased from $453,800 to $485,500. Received a 2023 bonus of $210,558, plus options for 50,000 shares, 12,000 RSUs, and 12,000 PSUs.
- Padmanabh P. Bhatt (CSO): Base salary increased from $427,700 to $440,500. Received a 2023 bonus of $163,165, plus options for 20,000 shares, 5,000 RSUs, and 5,000 PSUs.
- Jonathan Rubin (CMO): Base salary increased from $440,000 to $466,400. Received a 2023 bonus of $184,448, plus options for 25,000 shares, 5,000 RSUs, and 7,500 PSUs.
- Tami T. Martin (SVP, Regulatory): Base salary increased from $356,700 to $367,400. Received a 2023 bonus of $125,834. No equity grants listed in this summary.
- Frank Mottola (SVP, Quality/IT): Base salary increased from $352,700 to $377,400. Received a 2023 bonus of $129,361, plus options for 25,000 shares, 5,000 RSUs, and 7,500 PSUs.
Stock option exercise prices were set at $27.94 per share based on the closing price on February 22, 2024. Time-based options and RSUs vest annually over four years. PSUs vest based on performance goals.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or discuss specific risks or contingencies. Management commentary is limited to stating that the compensation increases are consistent with the Company's industry peer group and were recommended by Aon plc, the independent compensation consultant.
Investor Verification Checklist
- Verify the total dilution impact of the 592,000 stock options and 40,200 RSUs granted to executives.
- Review the specific performance goals attached to the 235,200 PSUs granted to determine vesting conditions.
- Confirm the total 2023 bonus payout of approximately $1.52 million to the six executives listed.
- Check the Company's 2023 Form 10-K (filed February 27, 2024) for the full text of the Option, RSU, and PSU agreements referenced in this filing.